Recent settlements between the U.S. Federal Trade Commission (FTC) and six CBD operators underscore the latest attempt to curtail long-running mislabeling concerns.
A new endeavor, Operation CBDeceit, now aims to crack down on CBD operators' deceptive claims that the drug treats medical conditions.
"The FTC is requiring each of the companies, and individuals behind them, to stop making such unsupported health claims immediately, and several will pay monetary judgments to the agency," says Braden Perry, a regulatory and government investigations attorney with Kansas City-based Kennyhertz Perry LLC.
The first-of-its-kind industry crackdown targeted six sellers and their unsubstantiated medical claims.